Hidetaka Tsumura
Hyogo Prefectural Cancer Center(JP)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Neuroendocrine Tumor Research Advances, Pancreatitis Pathology and Treatment, Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial(2019)694 cited
- → A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer(2013)187 cited
- → Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma(2022)121 cited
- → A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)(2022)76 cited
- → Needle tract seeding after endoscopic ultrasound‐guided tissue acquisition of pancreatic tumors: Nationwide survey in Japan(2022)52 cited
- → Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.(2018)39 cited
- → Clinical Factors of Delayed Perforation after Endoscopic Submucosal Dissection for Gastric Neoplasms(2017)29 cited
- → Diagnostic Reference Levels for Fluoroscopy-guided Gastrointestinal Procedures in Japan from the REX-GI Study: A Nationwide Multicentre Prospective Observational Study(2022)29 cited
- → Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in Japan(2007)26 cited
- → Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.(2018)19 cited